Difference between revisions of "Sebastian M, et al. Cancer Immunol. Immunother. (2007) cited as Ref 561 in DOI: 10.1038/s41392-020-0110-5 (Q9824)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: Publication Date (P100): 2007, #quickstatements; #temporary_batch_1590002823654)
(‎Created claim: Page(s) (P105): 1637-1644, #quickstatements; #temporary_batch_1590074839150)
 
(3 intermediate revisions by the same user not shown)
Property / Published In Name String
 +
Cancer Immunol. Immunother.
Property / Published In Name String: Cancer Immunol. Immunother. / rank
 +
Normal rank
Property / Volume
 +
56
Property / Volume: 56 / rank
 +
Normal rank
Property / title
 +
Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study (English)
Property / title: Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study (English) / rank
 +
Normal rank
Property / Page(s)
 +
1637-1644
Property / Page(s): 1637-1644 / rank
 +
Normal rank

Latest revision as of 15:45, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Sebastian M, et al. Cancer Immunol. Immunother. (2007) cited as Ref 561 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Sebastian M
    0 references
    0 references
    2007
    0 references
    Cancer Immunol. Immunother.
    0 references
    56
    0 references
    Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study (English)
    0 references
    1637-1644
    0 references